Blue Owl Capital Holdings’s enGene Therapeutics Warrants ENGNW Stock Holding History

Blue Owl Capital Holdings’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$148K	Hold	511,177	–	–	0.02%	46
2026 Q1	$1.29M	Buy	511,177 +475,077	+1,316%	+$1.41M	0.35%	35
2025 Q4	$103K	Hold	36,100	–	–	0.03%	51
2025 Q3	$25.6K	Hold	36,100	–	–	0.01%	55
2025 Q2	$29.6K	Hold	36,100	–	–	0.01%	54
2025 Q1	$21.7K	Hold	36,100	–	–	0.01%	53
2024 Q4	$30.4K	Sell	36,100 -475,077	-93%	-$701K	0.01%	55
2024 Q3	$728K	Buy	511,177 +460,000	+899%	+$543K	0.14%	48
2024 Q2	$608K	Sell	51,177 -460,000	-90%	-$1.47M	0.17%	36
2024 Q1	$2.66M	Buy	511,177 +36,100	+8%	+$110K	0.53%	31
2023 Q4	$404K	Buy	+475,077	New	+$365K	0.1%	38

Other funds holding ENGNW

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Blue Owl Capital Holdings's ENGNW Position: Q2 2026 in Review

Blue Owl Capital Holdings held its enGene Therapeutics Warrants (ENGNW) position steady in Q2 2026 at 511,177 shares worth $148K. The position accounts for 0.02% of the portfolio, ranked #46.

Blue Owl Capital Holdings first reported a position in ENGNW in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.66M in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

Blue Owl Capital Holdings held 511,177 shares of enGene Therapeutics Warrants worth $148K as of Q2 2026.
Blue Owl Capital Holdings left its enGene Therapeutics Warrants share count unchanged in Q2 2026.
enGene Therapeutics Warrants made up 0.02% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #46 holding.
Blue Owl Capital Holdings first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 11 quarters since.
Blue Owl Capital Holdings's enGene Therapeutics Warrants position peaked at $2.66M in Q1 2024.
11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.